Bulk Pharmaceutical API Sources for CARBACHOL

Bulk Pharmaceutical API Sources for CARBACHOL

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		C4382_SIGMA
Sigma-Aldrich		C2409_ALDRICH
TCI (Tokyo Chemical Industry)		C0596
Molport		MolPort-003-666-136
Amadis Chemical		A828807

Carbachol Bulk Active Pharmaceutical Ingredient Sources

Last updated: February 19, 2026

This analysis identifies key suppliers of bulk carbachol API, detailing production capacities, regulatory compliance, and market positioning. The data is critical for pharmaceutical manufacturers assessing supply chain diversification and sourcing strategies.

What is Carbachol?

Carbachol is a parasympathomimetic agent, specifically a choline ester. It acts as a cholinergic agonist, stimulating muscarinic and nicotinic acetylcholine receptors. Its primary therapeutic use is in ophthalmology, where it is administered topically to cause miosis (pupillary constriction) and to lower intraocular pressure in conditions like glaucoma. Carbachol's chemical structure features a quaternary ammonium group, contributing to its limited central nervous system penetration. The synthesis of carbachol typically involves the reaction of carbamoyl chloride with 2-chloroethanol, followed by quaternization with trimethylamine. The molecule's stability and formulation characteristics are key considerations in its API production.

Key Carbachol API Suppliers

The global market for carbachol API is served by a limited number of specialized manufacturers. These suppliers are characterized by their adherence to stringent quality control standards and regulatory requirements.

Primary Manufacturers

• Akorn, Inc. (USA): While primarily known as a finished dosage form manufacturer, Akorn has historically been involved in API sourcing and production for its internal needs and potentially for limited external sales. Their facility in Decatur, Illinois, has been a significant production site. Akorn's regulatory history, including FDA scrutiny, necessitates due diligence for any direct API procurement.
• Fresenius Kabi (Germany): A major global healthcare company with a significant API manufacturing division. Fresenius Kabi is known for producing a range of injectable and ophthalmic APIs. Their European manufacturing sites adhere to EMA and FDA Good Manufacturing Practices (GMP). Their production capacity for carbachol is substantial, catering to global pharmaceutical demand.
• Sandoz International GmbH (Switzerland): A division of Novartis, Sandoz is one of the world's largest generic drug manufacturers. They possess extensive API manufacturing capabilities across multiple global sites. Sandoz's carbachol API is likely produced under strict GMP conditions, with a focus on supplying their own finished product lines and select third-party clients. Their global footprint offers supply chain resilience.
• Carl Roth GmbH + Co. KG (Germany): Primarily a supplier of laboratory chemicals and reagents, Carl Roth also offers select pharmaceutical-grade APIs. While their scale may be smaller than major pharmaceutical chemical companies, they cater to specific niche markets and research needs, potentially offering carbachol in smaller, highly purified batches. Their adherence to German and EU quality standards is a key factor.
• Sigma-Aldrich (now part of Merck KGaA, Darmstadt, Germany): Similar to Carl Roth, Sigma-Aldrich is a broad supplier of research chemicals, biochemicals, and some pharmaceutical ingredients. Their portfolio includes carbachol, often in grades suitable for pharmaceutical development and research. The integration into Merck KGaA brings enhanced manufacturing and quality assurance capabilities.

Emerging and Niche Suppliers

• Indian API Manufacturers: Several Indian pharmaceutical companies, while not always publicly listing carbachol as a primary product, possess the chemical synthesis capabilities and regulatory infrastructure to produce it. Companies like Divi's Laboratories or Laurus Labs, known for their expertise in complex organic synthesis, could be engaged in carbachol production either as a custom synthesis project or as part of a broader ophthalmic API portfolio. Verification of their specific GMP certifications and current production status for carbachol is essential.
• Chinese API Manufacturers: The Chinese pharmaceutical ingredient sector offers a vast array of chemical synthesis services. While specific carbachol producers might not be widely advertised, contract manufacturing organizations (CMOs) with expertise in esterification and quaternization reactions are potential sources. Due diligence regarding quality control, regulatory compliance (e.g., FDA inspections, CEP certification), and intellectual property is paramount when engaging with Chinese suppliers.

Production Capacity and Market Dynamics

Carbachol is a well-established API with a mature market. Production volumes are generally stable, driven by the consistent demand for glaucoma treatment.

• Production Scale: Major suppliers like Fresenius Kabi and Sandoz operate large-scale facilities capable of producing metric tons of API annually. Niche suppliers and CMOs may operate at smaller scales, catering to specialized requirements or initial market entry.
• Regulatory Landscape: All API suppliers for pharmaceutical use must comply with Good Manufacturing Practices (GMP). For products intended for the US market, FDA GMP compliance is mandatory, often verified through facility inspections. For the European market, EMA regulations and potentially a Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) are critical.
• Pricing Factors: API pricing is influenced by raw material costs, synthesis complexity, production volume, regulatory compliance costs, and market competition. Carbachol, being a relatively simple molecule, generally exhibits stable pricing, with variations occurring due to supply chain disruptions or significant shifts in raw material availability.
• Supply Chain Risks: Potential risks include reliance on single suppliers, geopolitical instability affecting raw material sourcing, and stringent regulatory enforcement that can lead to production halts or recalls. Diversifying the supplier base is a key risk mitigation strategy.

Regulatory Compliance and Quality Standards

Ensuring the quality and regulatory compliance of carbachol API is paramount for patient safety and product efficacy.

Key Regulatory Requirements

• Good Manufacturing Practices (GMP): Facilities must adhere to current GMP standards (e.g., ICH Q7 for APIs). This covers facility design, equipment validation, process controls, quality control testing, documentation, and personnel training.
• Drug Master Files (DMFs): Suppliers often maintain DMFs with regulatory agencies (e.g., FDA, EMA). These confidential documents provide detailed information about the API manufacturing process, quality controls, and stability data, which are reviewed by regulatory authorities during the approval of finished drug products.
• Pharmacopoeial Standards: Carbachol API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs define tests for identity, purity, assay, and impurities.
• Impurity Profiling: Manufacturers must rigorously identify, quantify, and control process-related impurities and degradation products. This includes residual solvents, heavy metals, and specific organic impurities.

Quality Control Measures

• Analytical Testing: Comprehensive analytical testing is performed on raw materials, in-process samples, and the final API. This includes techniques such as High-Performance Liquid Chromatography (HPLC) for assay and impurity determination, Gas Chromatography (GC) for residual solvents, Karl Fischer titration for water content, and spectroscopic methods (IR, NMR) for identity confirmation.
• Stability Studies: API batches undergo stability testing under various temperature and humidity conditions to establish shelf life and recommended storage conditions. This data is crucial for product registration and ongoing quality monitoring.
• Audits and Inspections: Pharmaceutical companies routinely audit their API suppliers to ensure ongoing compliance with quality agreements and regulatory standards. Regulatory agencies also conduct inspections of API manufacturing facilities.

Sourcing Strategies for Pharmaceutical Manufacturers

Effective sourcing of carbachol API involves a multi-faceted approach to ensure supply reliability, quality, and cost-effectiveness.

Due Diligence and Supplier Qualification

1. Regulatory Status Verification: Confirm that the supplier's manufacturing site is registered and approved by relevant health authorities (FDA, EMA, etc.) for the intended markets. Review inspection reports and enforcement actions.
2. Quality System Assessment: Evaluate the supplier's quality management system. This includes reviewing their quality manual, change control procedures, deviation management, and CAPA (Corrective and Preventive Actions) systems.
3. GMP Compliance Documentation: Request evidence of GMP certification, including recent audit reports from regulatory bodies or third-party auditors.
4. Technical Capabilities Review: Assess the supplier's process validation, impurity control strategies, and analytical method validation.
5. DMF Review: If a DMF is available, review it for completeness and adequacy.

Supply Chain Risk Management

• Dual Sourcing: Identify and qualify at least two independent API suppliers to mitigate risks associated with single-source dependency.
• Geographic Diversification: Source APIs from suppliers located in different geographic regions to reduce exposure to regional political or economic instability.
• Inventory Management: Maintain appropriate safety stock levels of critical APIs to buffer against unexpected supply disruptions.
• Contingency Planning: Develop robust contingency plans for alternative sourcing or manufacturing should a primary supplier face issues.

Contractual Agreements

• Quality Agreements: Establish comprehensive quality agreements that clearly define roles, responsibilities, quality standards, and reporting requirements.
• Supply Agreements: Negotiate clear supply agreements that specify pricing, delivery schedules, order volumes, lead times, and provisions for force majeure.
• Confidentiality Agreements: Ensure appropriate confidentiality agreements are in place to protect proprietary information.

Key Takeaways

• The carbachol API market is characterized by established global players and a need for rigorous quality and regulatory adherence.
• Key suppliers include Fresenius Kabi, Sandoz, Akorn, Carl Roth, and Sigma-Aldrich, with potential for niche or custom synthesis from Indian and Chinese manufacturers.
• Verification of GMP compliance, DMF status, and pharmacopoeial adherence is critical for API selection.
• Pharmaceutical manufacturers must implement robust supplier qualification, quality assurance, and supply chain risk management strategies, including dual sourcing.

FAQs

1. What are the primary regulatory bodies that oversee carbachol API manufacturing for global markets?

The primary regulatory bodies include the U.S. Food and Drug Administration (FDA) for the United States, the European Medicines Agency (EMA) for the European Union, and national regulatory authorities in other regions.

2. What is a Drug Master File (DMF) and why is it important for carbachol API sourcing?

A Drug Master File (DMF) is a submission to a regulatory agency that provides confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. For carbachol API, a DMF allows the API manufacturer to protect proprietary information while enabling regulatory agencies to review the API's manufacturing details when assessing finished drug product applications.

3. How can pharmaceutical manufacturers assess the impurity profile of a carbachol API supplier?

Manufacturers should request detailed impurity profiles from suppliers, including data on known process impurities, degradation products, residual solvents, and heavy metals, as per pharmacopoeial limits. This data should be supported by validated analytical methods, and suppliers should have robust impurity control strategies in place.

4. What are the typical lead times for sourcing carbachol API from established suppliers?

Lead times can vary significantly but typically range from 4 to 12 weeks for standard orders from established, high-volume suppliers. Niche suppliers or custom synthesis projects may have longer lead times. It is essential to confirm specific lead times with each potential supplier.

5. Are there specific pharmacopoeial monographs for carbachol API, and which ones are most commonly referenced?

Yes, there are pharmacopoeial monographs for carbachol. The most commonly referenced are the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). Manufacturers must ensure their API meets the specifications outlined in the relevant pharmacopoeia for the target market.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files

[2] European Medicines Agency. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/marketing-authorisation/procedural-advice/certificate-suitability-monographs-european-pharmacopoeia-cep

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1998). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7.

[4] United States Pharmacopeia. (n.d.). USP Monograph Database. (Accessed by subscription).

[5] European Pharmacopoeia. (n.d.). Ph. Eur. Monograph Database. (Accessed by subscription).